BR112012003107A2 - composição farmacêutica, compreendendo um éster de dha, destinada a ser administrada por via parenteral - Google Patents

composição farmacêutica, compreendendo um éster de dha, destinada a ser administrada por via parenteral

Info

Publication number
BR112012003107A2
BR112012003107A2 BR112012003107A BR112012003107A BR112012003107A2 BR 112012003107 A2 BR112012003107 A2 BR 112012003107A2 BR 112012003107 A BR112012003107 A BR 112012003107A BR 112012003107 A BR112012003107 A BR 112012003107A BR 112012003107 A2 BR112012003107 A2 BR 112012003107A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
parenteral administration
dha ester
intended
ester intended
Prior art date
Application number
BR112012003107A
Other languages
English (en)
Inventor
Elie Leverd
Elsa Kung
Mathew Leigh
Peter Van Hoogevest
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BR112012003107A2 publication Critical patent/BR112012003107A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112012003107A 2009-08-11 2010-08-11 composição farmacêutica, compreendendo um éster de dha, destinada a ser administrada por via parenteral BR112012003107A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0955612A FR2949063B1 (fr) 2009-08-11 2009-08-11 Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
PCT/EP2010/061701 WO2011018480A1 (fr) 2009-08-11 2010-08-11 Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale

Publications (1)

Publication Number Publication Date
BR112012003107A2 true BR112012003107A2 (pt) 2016-02-23

Family

ID=42062409

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012003107A BR112012003107A2 (pt) 2009-08-11 2010-08-11 composição farmacêutica, compreendendo um éster de dha, destinada a ser administrada por via parenteral

Country Status (22)

Country Link
US (1) US8753652B2 (pt)
EP (1) EP2464335B1 (pt)
JP (2) JP5847714B2 (pt)
KR (1) KR101735861B1 (pt)
CN (1) CN102470104B (pt)
AU (1) AU2010283754B2 (pt)
BR (1) BR112012003107A2 (pt)
CA (1) CA2770262C (pt)
ES (1) ES2566359T3 (pt)
FR (1) FR2949063B1 (pt)
GE (1) GEP20146088B (pt)
HU (1) HUE026807T2 (pt)
IL (1) IL217988A (pt)
MA (1) MA33518B1 (pt)
MX (1) MX2012001718A (pt)
NZ (1) NZ598082A (pt)
PL (1) PL2464335T3 (pt)
RU (1) RU2535029C2 (pt)
TN (1) TN2012000044A1 (pt)
UA (1) UA108477C2 (pt)
WO (1) WO2011018480A1 (pt)
ZA (1) ZA201200714B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2963790B1 (fr) * 2010-08-11 2012-09-28 Pf Medicament Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
WO2013123466A1 (en) 2012-02-16 2013-08-22 Brightside Innovations, Inc. Dietary and nutritional compositions and methods of use
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
FR2998479B1 (fr) * 2012-11-27 2017-04-28 Pf Medicament Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose
US11278493B2 (en) * 2018-12-10 2022-03-22 EternaTear, Inc. Ophthalmic formulations providing durable ocular lubrication

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760081A (en) * 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
DE19609477A1 (de) * 1996-03-11 1997-09-18 Basf Ag Stabile wäßrige Solubilisate von Carotinoiden und Vitamine
WO1998007414A1 (en) * 1996-08-22 1998-02-26 Research Triangle Pharmaceuticals Ltd. Compositions comprising microparticles of water-insoluble substances and method for preparing same
TWI241915B (en) * 1998-05-11 2005-10-21 Ciba Sc Holding Ag A method of preparing a pharmaceutical end formulation using a nanodispersion
EP1192178A2 (en) * 1999-06-21 2002-04-03 Eli Lilly And Company Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistance associated protein-1 (mrp-1)
AUPQ480399A0 (en) 1999-12-22 2000-02-03 Commonwealth Scientific And Industrial Research Organisation Unsaturated fatty acids and their uses in therapy
FR2805761B1 (fr) * 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
US20050214378A1 (en) * 2002-06-11 2005-09-29 Ethypharm Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
KR100482269B1 (ko) * 2002-10-08 2005-04-14 센츄론(주) 2,6-디이소프로필페놀을 활성성분으로 하는 수용액상의마취용 주사제 및 그 제조방법
WO2004078166A2 (en) * 2003-03-05 2004-09-16 Solvay Pharmaceuticals Gmbh Use of omega-3-fatty acids in the treatment of diabetic patients
KR101245022B1 (ko) * 2005-01-21 2013-03-19 카무러스 에이비 약제학적 지질 조성물
FR2902659A1 (fr) * 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
CN101091890A (zh) * 2007-07-26 2007-12-26 沈阳药科大学 一种复合型乳化剂及用其制备的乳剂及其制备方法
CN101259102B (zh) * 2008-04-17 2011-05-25 湖北福星生物科技有限公司 一种微米级二十二碳六烯酸乳状液及其制备方法
CN101385714B (zh) * 2008-10-24 2011-07-27 苏州纳康生物科技有限公司 Dha脂质纳米粒的制备方法

Also Published As

Publication number Publication date
ES2566359T3 (es) 2016-04-12
US20120141563A1 (en) 2012-06-07
HUE026807T2 (en) 2016-07-28
FR2949063A1 (fr) 2011-02-18
HK1170169A1 (en) 2013-02-22
MA33518B1 (fr) 2012-08-01
CA2770262A1 (fr) 2011-02-17
KR101735861B1 (ko) 2017-05-15
IL217988A0 (en) 2012-03-29
RU2535029C2 (ru) 2014-12-10
JP6050440B2 (ja) 2016-12-21
RU2012108049A (ru) 2013-09-20
TN2012000044A1 (fr) 2013-09-19
JP5847714B2 (ja) 2016-01-27
JP2013501752A (ja) 2013-01-17
CN102470104B (zh) 2014-05-14
GEP20146088B (en) 2014-05-13
WO2011018480A1 (fr) 2011-02-17
IL217988A (en) 2016-05-31
NZ598082A (en) 2013-08-30
MX2012001718A (es) 2012-04-02
ZA201200714B (en) 2013-06-26
PL2464335T3 (pl) 2016-06-30
UA108477C2 (uk) 2015-05-12
US8753652B2 (en) 2014-06-17
JP2016000742A (ja) 2016-01-07
EP2464335B1 (fr) 2016-01-06
CN102470104A (zh) 2012-05-23
FR2949063B1 (fr) 2011-09-30
EP2464335A1 (fr) 2012-06-20
AU2010283754A1 (en) 2012-03-08
CA2770262C (fr) 2016-12-06
AU2010283754B2 (en) 2014-05-08
KR20120047949A (ko) 2012-05-14

Similar Documents

Publication Publication Date Title
IL207512A0 (en) Pharmaceutical composition for poorly soluble drugs
ZA201006029B (en) Pharmaceutical dosage form
EP2381773A4 (en) COMPOSITIONS FOR THE ADMINISTRATION OF MEDICINAL PRODUCTS
ZA201005015B (en) Solid pharmaceutical dosage form
EP2451274A4 (en) Pharmaceutical compositions
EP2419097A4 (en) PHARMACEUTICAL COMPOSITIONS
BRPI0920514A2 (pt) infusão de fármacos
BRPI1015996A8 (pt) composições farmacêuticas aquosas contendo complexos de borato-poliol
IL216256A0 (en) A pharmaceutical composition
IL219699B (en) Cyclodextrin-based polymers for therapeutic delivery
ZA201006227B (en) Pharmaceutical compositions having desirable bioavailability
SI2285413T1 (sl) Farmacevtski sestavek
IL210393A0 (en) Administration regime for nitrocatechols
ZA201109138B (en) Pharmaceutical composition having improved solubility
ZA201105572B (en) Pharmaceutical composition for oral administration
ZA200903858B (en) Pharmaceutical dosage form
BR112012003107A2 (pt) composição farmacêutica, compreendendo um éster de dha, destinada a ser administrada por via parenteral
BRPI0806938A2 (pt) Composição farmacêutica contedo um derivado de camptotecina
ZA201008115B (en) A solid pharmaceutical formulation
IL212603A0 (en) Combined drug administration
BRPI0922623A2 (pt) comprimido farmacêutico de liberação controlada
IL196099A0 (en) Pharmaceutical composition for administration by injection
EP2521539A4 (en) INJECTABLE PREPARATIONS FOR PARENTERAL ADMINISTRATION
ZA201102405B (en) Pharmaceutical composition for oral administration
EP2473168A4 (en) PHARMACEUTICAL FORMULATIONS FOR INDIBULIN

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]